Ovid Therapeutics (OVID) Equity Average (2020 - 2025)
Historic Equity Average for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $50.2 million.
- Ovid Therapeutics' Equity Average fell 3916.99% to $50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 3916.99%. This contributed to the annual value of $78.0 million for FY2024, which is 2910.29% down from last year.
- Latest data reveals that Ovid Therapeutics reported Equity Average of $50.2 million as of Q3 2025, which was down 3916.99% from $57.5 million recorded in Q2 2025.
- In the past 5 years, Ovid Therapeutics' Equity Average ranged from a high of $213.9 million in Q2 2021 and a low of $50.2 million during Q3 2025
- For the 5-year period, Ovid Therapeutics' Equity Average averaged around $120.4 million, with its median value being $115.8 million (2023).
- Per our database at Business Quant, Ovid Therapeutics' Equity Average surged by 42219.14% in 2021 and then plummeted by 3916.99% in 2025.
- Quarter analysis of 5 years shows Ovid Therapeutics' Equity Average stood at $188.4 million in 2021, then fell by 27.19% to $137.2 million in 2022, then tumbled by 31.07% to $94.5 million in 2023, then decreased by 23.57% to $72.3 million in 2024, then plummeted by 30.47% to $50.2 million in 2025.
- Its last three reported values are $50.2 million in Q3 2025, $57.5 million for Q2 2025, and $63.8 million during Q1 2025.